Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT.

Authors :: Zahed H
Beauregard JM
Abikhzer G
Rush C
Probst S
Source :: Clinical nuclear medicine [Clin Nucl Med] 2023 Jan 01; Vol. 48 (1), pp. e12-e15. Date of Electronic Publication: 2022 Oct 14.
Publication Year :: 2023
Abstract: Abstract: 68 Ga-DOTATATE PET/CT is indicated for selecting patients for peptide receptor radionuclide therapy (PRRT). Although highly sensitive, the detectability of smaller lesions, particularly in the liver, is lower. We present the case of a 58-year-old man with metastatic well-differentiated pancreatic neuroendocrine tumor whose MRI revealed progression of hepatic metastases. 68 Ga-DOTATATE PET/CT performed to determine eligibility for PRRT did not demonstrate DOTATATE-avid disease within the liver. 18 F-FDG PET/CT was also negative at the liver and the patient proceeded to 177 Lu-DOTATATE PRRT, where multi-time point posttherapy planar imaging and SPECT/CT showed intense uptake in the known liver metastases.<br />Competing Interests: Conflicts of interest and sources of funding: none declared.<br /> (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)

Subjects :: Male
Humans
Middle Aged
Positron Emission Tomography Computed Tomography methods
Gallium Radioisotopes
Radiopharmaceuticals
Single Photon Emission Computed Tomography Computed Tomography
Neuroendocrine Tumors diagnostic imaging
Neuroendocrine Tumors pathology
Organometallic Compounds
Liver Neoplasms diagnostic imaging

Full Text Access

Tools